Glepaglutide is under clinical development by Zealand Pharma and currently in Pre-Registration for Short Bowel Syndrome. According to GlobalData, Pre-Registration drugs for Short Bowel Syndrome have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Glepaglutide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Glepaglutide overview
Glepaglutide (ZP-1848) is under development for the treatment of short bowel syndrome (SBS). ZP1848 is a long acting SIP-modified glucagon-like peptide-2 (GLP-2) analogue. It is administered as a solution through subcutaneous route. It is developed based on SIP technology. The SIP-technology is a protein modification technology. It was also under development for the treatment of Crohn’s disease.
Zealand Pharma overview
Zealand Pharma (Zealand) is a biotechnology company that discovers and develops peptide-based medicines. The company’s pipeline products include liraglutide, a long-acting GLP-2 analog in development for the treatment of short bowel syndrome; dasiglucagon for congenital hyperinsulinism and bi-hormonal artificial pancreas systems; survodutide (BI 456906) treats obesity and nonalcoholic steatohepatitis; ZP8396 for overweight and obesity; dapiglutide for obesity. Zealand conducts research and development and in-licensing programs. It has operations in Denmark and the US. Zealand is headquartered in Soeborg, Denmark.
For a complete picture of Glepaglutide’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
